Editas Medicine, Inc. (EDIT)
2.70
+0.05
(+1.89%)
USD |
NASDAQ |
Sep 11, 16:00
2.70
0.00 (0.00%)
After-Hours: 07:32
Editas Medicine Enterprise Value : 274.14M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 274.14M |
| September 10, 2026 | 266.46M |
| September 09, 2026 | 284.88M |
| September 08, 2026 | 324.80M |
| September 04, 2026 | 355.51M |
| September 03, 2026 | 332.48M |
| September 02, 2026 | 332.48M |
| September 01, 2026 | 330.94M |
| August 31, 2026 | 329.41M |
| August 28, 2026 | 344.76M |
| August 27, 2026 | 366.26M |
| August 26, 2026 | 347.83M |
| August 25, 2026 | 363.19M |
| August 24, 2026 | 320.20M |
| August 21, 2026 | 337.09M |
| August 20, 2026 | 310.98M |
| August 19, 2026 | 358.58M |
| August 18, 2026 | 301.77M |
| August 17, 2026 | 295.63M |
| August 14, 2026 | 292.56M |
| August 13, 2026 | 291.03M |
| August 12, 2026 | 295.63M |
| August 11, 2026 | 312.52M |
| August 10, 2026 | 291.03M |
| August 07, 2026 | 301.77M |
| Date | Value |
|---|---|
| August 06, 2026 | 304.84M |
| August 05, 2026 | 281.81M |
| August 04, 2026 | 284.88M |
| August 03, 2026 | 266.46M |
| July 31, 2026 | 255.71M |
| July 30, 2026 | 272.60M |
| July 29, 2026 | 258.78M |
| July 28, 2026 | 261.86M |
| July 27, 2026 | 271.07M |
| July 24, 2026 | 258.78M |
| July 23, 2026 | 278.74M |
| July 22, 2026 | 286.42M |
| July 21, 2026 | 303.31M |
| July 20, 2026 | 301.77M |
| July 17, 2026 | 317.13M |
| July 16, 2026 | 301.77M |
| July 15, 2026 | 326.34M |
| July 14, 2026 | 344.76M |
| July 13, 2026 | 344.76M |
| July 10, 2026 | 360.11M |
| July 09, 2026 | 366.26M |
| July 08, 2026 | 423.06M |
| July 07, 2026 | 435.34M |
| July 06, 2026 | 419.99M |
| July 02, 2026 | 419.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Recursion Pharmaceuticals, Inc. | 1.225B |
| Geron Corp. | 816.37M |
| Halozyme Therapeutics, Inc. | 14.14B |
| Novavax, Inc. | 1.131B |
| AVITA Medical, Inc. | 342.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.23M |
| Revenue (Quarterly) | 11.89M |
| Total Expenses (Quarterly) | 30.12M |
| EPS Diluted (Quarterly) | -0.1528 |
| Gross Profit Margin (Quarterly) | 96.50% |
| Profit Margin (Quarterly) | -153.3% |
| Earnings Yield | -27.58% |
| Normalized Earnings Yield | -29.54 |